Clinical trial

Funding concept
#Clinical trial #Funding #LIfT BioSciences #Oncology #Solid tumours

LIfT BioSciences receives €12m to support solid tumour trials

LIfT BioSciences has received a grant of €12 million from Ireland’s Disruptive Technologies Innovation Fund (DTIF) to advance its Immuno-Modulatory Alpha Neutrophils (IMANs), designed to overcome treatment resistance in solid tumours, through first-in-human clinical trials expected to start in Q4 2026.  The €12 million grant, the largest grant awarded by… Read More

#Business & Investment #News

#Atsena Therapeutics #Clinical trial #FDA #Gene therapy #Ophthalmology

Atsena expedites gene therapy for X-linked retinoschisis

The US Food and Drug Administration (FDA) has agreed to the expansion of Atsena Therapeutics’ ongoing Phase I/II LIGHTHOUSE study of ATSN-201 into a continuous Phase I/II/III trial in the treatment of X-linked retinoschisis (XLRS).   “This regulatory milestone marks another significant step toward delivering a potentially first- and best-in-class gene… Read More

#News #Regulatory

Test for AMD
#Cell therapy #Clinical trial #Lineage Cell Therapeutics #Ophthalmology

Cell therapy improves visual function in geographic atrophy patients

Lineage Cell Therapeutics revealed new 36-month results from a Phase I/IIa clinical study of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) at Clinical Trials at the Summit (CTS) 2025.   OpRegen is a suspension of human allogeneic retinal pigment epithelial (RPE)… Read More

#News

Human cell
#Cell therapy #Clinical trial #Diabetes #Type 1 diabetes #Vertex

Vertex shares new data for stem cell-derived islet therapy in T1D

Vertex Pharmaceuticals has shared new Phase I/II data for zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy.  The FORWARD-101 clinical trial is investigating the treatment in people with type 1 diabetes (T1D) with impaired hypoglycaemic awareness and severe hypoglycaemic events (SHEs).  All… Read More

#News

#Clinical trial #Cystic fibrosis #Events #Vertex

Data shows improved quality of life with CFTR modulators

Vertex Pharmaceuticals has shared data demonstrating the positive clinical and quality of life benefits of treatment with cystic fibrosis transmembrane conductance regulator (CFTR) modulators and in particular, Alyftrek (deutivacaftor/tezacaftor/vanzacaftor).  These data were presented at the European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held 4-7… Read More

#News

Neuroendocrine tumours
#ASCO #Clinical trial #Oncology #Perspective Therapeutics #Radiopharmaceuticals

Perspective shares positive responses in NETs at ASCO

Perspective Therapeutics has shared interim results from its ongoing Phase I/IIa clinical trial of [212Pb]VMT-α-NET at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.  The Phase I/IIa clinical trial is a multi-centre open-label dose escalation and dose expansion study of [212Pb]VMT-α-NET in patients with unresectable… Read More

#Cancer Research #News

Pfizer, New York
#Clinical trial #GLP-1 #Pfizer #Weight loss

Pfizer discontinues oral GLP-1 receptor agonist danuglipron

Pfizer has announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, due to drug-induced liver injury.  Danuglipron (PF-06882961) was being investigated for chronic weight management.  The company’s dose-optimisation studies of once-daily formulations of danuglipron met key pharmacokinetic objectives and confirmed a formulation and dose… Read More

#Business & Investment #News #Trending News

Cholesterol test
#AstraZeneca #Cardiovascular disease #Cholesterol #Clinical trial

PCSK9 inhibitor demonstrates significant cholesterol reduction

Positive results from the PURSUIT Phase IIb trial for AstraZeneca’s AZD0780 have demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of standard-of-care statin therapy.  AZD0780 is an investigational once-daily oral PCSK9 inhibitor for patients currently not reaching their LDL-C lowering goal despite… Read More

#News

Lung cancer
#Clinical trial #Johnson & Johnson #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology

Rybrevant and Lazcluze extend survival in NSCLC

Results from its first-line MARIPOSA trial show that Rybrevant (amivantamab) plus Lazcluze (lazertinib) significantly extended overall survival (OS) versus osimertinib in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).  The patients have NSCLC with epidermal growth factor receptor (EGFR)… Read More

#News

Monoclonal antibody
#Bluejay Therapeutics #Clinical trial #hepatitis #Monoclonal antibodies #Viral hepatitis

Trial investigates monoclonal antibody for chronic hepatitis D

Bluejay Therapeutics’ AZURE-1 global pivotal clinical trial evaluating brelovitug (BJT-778) for the treatment of chronic hepatitis D (CHD) has dosed its first patient.   Brelovitug is an investigational fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets the surface antigen (anti-HBsAg) on both the hepatitis D virus… Read More

#News

Weight loss concept
#Clinical trial #Obesity #Oxford Medical Products #Weight loss

New generation in weight-loss therapies targets overweight

Oxford Medical Products (OMP) has announced additional three-month clinical trial results for Sirona, its weight-loss treatment targeting people who are overweight or have class I obesity (BMI 25-35) and those transitioning off GLP-1 medication.   The clinical trial took place across three NHS hospitals in the UK and… Read More

#News

Gene editing
#Base editing #Beam Therapeutics #Clinical trial #Gene editing #Gene therapy #mRNA

First clinical genetic correction of a disease-causing mutation reported

Biotechnology company Beam Therapeutics says initial data from its Phase I/II trial establish clinical proof-of-concept for BEAM-302 as a potential treatment for alpha-1 antitrypsin deficiency (AATD) and for in vivo base editing.  Preliminary results from the first three single-ascending dose cohorts demonstrated that BEAM-302 was… Read More

#Editor's Choice #News

Blood samples in lab
#blood #Clinical trial #Fc-Fusion proteins #Proteins #Rare disease #Thrombotic diseases

First patients dosed in thrombolytic drug trial

TargED Biopharmaceuticals, a biotechnology company focused on developing improved treatments for thrombotic diseases, has dosed the first participant with TGD001. TGD001 is a thrombolytic designed to break down clots of all sizes and compositions – from large clots which cause AIS, down to ‘micro-clots’ which cause conditions such as the… Read More

#News

FDA
#Clinical trial #Drug discovery #FDA #Regulatory #SpliceBio #Stargardt disease

First-ever FDA IND for a protein splicing gene therapy

The US Food & Drug Administration (FDA) has cleared an investigational new drug (IND) application for SpliceBio’s lead programme SB-007, a clinical-stage therapeutic addressing the root genetic cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations. The SpliceBio study uses protein splicing to address… Read More

#News #Regulatory #Trending News

#AI / data analytics / healthtech / informatics #Clinical trial #Clinical trial design #Phesi

Over collection of data delays clinical trials, report finds

A significant number of Phase III clinical trials are over-collecting data because of overcomplicated protocol designs, leading to avoidable delays in drug development times, says a new report.  Phesi used proprietary data from its Trial Accelerator Platform to analyse 2,401 industry-sponsored Phase III clinical trials that have… Read More

#News

#Clinical trial #Duchenne muscular dystrophy #Gene therapy #REGENXBIO

Gene therapy positively impacts Duchenne disease trajectory

AFFINITY DUCHENNE, a multi-centre, open-label trial of gene therapy RGX-202 for Duchenne muscular dystrophy has dosed its first patient, REGENXBIO has announced. The company also revealed new, positive efficacy and safety data from the Phase I/II portion of the study, including the first functional data. Read More

#News